Funding news · Oct 22, 2026
TriOar Raises KRW 33B Series C+ for ADC Platforms and Pipeline
TriOar Secures KRW 33 Billion Series C+
TriOar (트리오어), a South Korean biotech developing antibody-based therapeutics and antibody-drug conjugates (ADCs) for oncology, has raised KRW 33 billion in a Series C+ round. The round drew a broad investor group including HB Investment, Korea Development Bank, Woori Venture Partners, Shinhan Capital, DS Asset Management, LSK Investment, Sage One Partners, TES Investment Partners, Honeypot Ventures and Sneak Peek Investment.
What the Company Does
Founded in 2021 by Dr. Sung Ho Woo and based in Daejeon, TriOar develops next-generation antibody-based therapeutics and ADCs for oncology. The company's work is built on two proprietary platforms:
- TROCAD — a dual-function conditionally activated masking technology
- TROSIG — a self-immolative linker-payload system
Both platforms are designed to improve tumor selectivity and the therapeutic index of ADCs. They underpin internal candidates including TRO-01, which targets CLDN18.2, and TRO-02, which targets EGFR; both were presented at AACR 2026.
Commercialization Strategy
TriOar pursues commercialization through co-development and technology-transfer deals with domestic and global pharma. This includes a platform licensing and joint development agreement with Celltrion. The company operates out of the Seoul Biohub startup support program.
The Round
| Detail | Value |
|---|---|
| Round type | Series C+ |
| Amount | KRW 33,000,000,000 |
| Date | October 22, 2026 |
| Lead investor | Not disclosed |
| Investors | HB Investment, Korea Development Bank, Woori Venture Partners, Shinhan Capital, DS Asset Management, LSK Investment, Sage One Partners, TES Investment Partners, Honeypot Ventures, Sneak Peek Investment |
Why It Matters for Acquisition Watchers
TriOar's value sits in its platform technologies rather than a single asset. TROCAD and TROSIG address two of the central engineering problems in ADC development — tumor selectivity and linker-payload design — and a platform that improves the therapeutic index can be applied across multiple targets and programs. That makes the company a candidate for pharma partners seeking differentiated ADC toolkits, as well as for acquirers interested in licensing or absorbing platform IP.
The existing Celltrion platform licensing and joint development agreement is a concrete validation point: a named pharma counterparty has already engaged with the technology. The AACR 2026 presentations of TRO-01 (CLDN18.2) and TRO-02 (EGFR) give the internal pipeline visible, target-specific programs in well-trafficked oncology spaces.
The Series C+ structure — a follow-on to an earlier Series C — with a wide syndicate spanning venture capital, a policy bank (Korea Development Bank), and strategic financial investors suggests continued institutional support as the company advances its platforms and pipeline. For acquirers and partners, TriOar offers a Korean oncology ADC platform with disclosed preclinical data, an existing pharma collaboration, and a maturing investor base.
Key Takeaways
- TriOar raised KRW 33 billion in Series C+ funding on October 22, 2026.
- The round included HB Investment, Korea Development Bank, Woori Venture Partners, Shinhan Capital, DS Asset Management, LSK Investment, Sage One Partners, TES Investment Partners, Honeypot Ventures and Sneak Peek Investment.
- TriOar was founded in 2021 by Dr. Sung Ho Woo and is based in Daejeon, South Korea.
- Its platforms are TROCAD (conditionally activated masking) and TROSIG (self-immolative linker-payload).
- Internal candidates TRO-01 (CLDN18.2) and TRO-02 (EGFR) were presented at AACR 2026.
- The company has a platform licensing and joint development agreement with Celltrion.